All In Biotech

Drug Trial Radar · NCT05410860

Efficacy and Safety Study of Etripamil Nasal Spray Self-Administration for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia

Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Etripamil Nasal Spray Self-Administration for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia in Chinese Patients

Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 500 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

500

Actual

Start

Jun 30, 2022

Primary completion

Aug 2, 2024

Study completion Dec 10, 2024

Sponsor

Lead sponsor
Corxel PharmaceuticalsIndustry
Sponsor type
Industry
Collaborators
Milestone Pharmaceuticals Inc.
First posted
Jun 8, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To determine whether etripamil nasal spray (NS) self-administered by Chinese patients is superior to placebo at terminating episodes of PSVT in an at-home setting; To evaluate the efficacy of etripamil NS self-administered by Chinese patients compared with placebo on a range of clinical markers. To evaluate the safety of etripamil NS self-administered by Chinese patients compared with placebo

Conditions

  • Tachycardia, Supraventricular
  • Paroxysmal Supraventricular Tachycardia

Interventions

  • Etripamil NS 70 mgDrug

    Etripamil NS 70 mg will be administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.

  • PlaceboDrug

    Placebo will be administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to an adjudicated termination of a positively adjudicated episode of PSVT and conversion to sinus rhythm (SR) for at least 30 seconds within 30 minutes of start of study drug dosingTime frame: Within 30 minutes of start of study drug dosing.

Locations

53 sites in 1 country. Site status is shown where the registry gives one.

  • Baotou Central Hospital

    Baotou, China

  • The First Affiliated Hospital of Baotou Medical College

    Baotou, China

  • Beijing Anzhen Hospital; Capital Medical University

    Beijing, China

  • Beijing Hospital

    Beijing, China

  • Beijing Tongren Hospital, Capital Medical University

    Beijing, China

  • Chui Yang Liu Hospital Affiliated to Tsinghua University

    Beijing, China

  • Peking Union Medical College Hospital

    Beijing, China

  • The Central Hospital of China Aerospace Corporation

    Beijing, China

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, China

  • The First Hospital of Jilin University

    Ch’ang-ch’un, China

  • The Third Xiangya Hospital of Central South University

    Changsha, China

  • Xiangya Hospital, Central South University

    Changsha, China

  • Changzhou No.2 People's Hospital

    Changzhou, China

  • The First Affiliated Hospital of Chengdu Medical College

    Chengdu, China

  • Affiliated Zhongshan Hospital of Dalian University

    Dalian, China

  • People's Hospital of Deyang City

    Deyang, China

  • The First Affiliated Hospital of Fujian Medical University

    Fuzhou, China

  • Nanfang Hospital of Southern Medical University

    Guangzhou, China

  • Guizhou Provincial People's Hospital

    Guiyang, China

  • Sir Run Run Shaw Hospital, Zhejiang University School of Medicine

    Hangzhou, China

  • The First People's Hospital of Hangzhou Linping District

    Hangzhou, China

  • Zhejiang Provincial People's Hospital

    Hangzhou, China

  • Huai'an First People's Hospital

    Huai'an, China

  • Huainan First People's Hospital

    Huainan, China

  • Huizhou Municipal Central Hospital

    Huizhou, China

  • Jinan Central Hospital

    Jinan, China

  • Shandong Province Qianfoshan Hospital

    Jinan, China

  • The First Affiliated Hospital of Jinzhou Medical University

    Jinzhou, China

  • Lanzhou University Second Hospital

    Lanzhou, China

  • Lishui Municipal Central Hospital

    Lishui, China

  • The First Affiliated Hospital of Henan Science and Technology University

    Luoyang, China

  • Mianyang Central Hospital

    Mianyang, China

  • The Nanchang Third Hospital

    Nanchang, China

  • The Second Affiliated Hospital of Nanchang University

    Nanchang, China

  • Jiangsu Province Hospital

    Nanjing, China

  • Nanjing Drum Tower Hospital

    Nanjing, China

  • Guangxi Zhuang Autonomous Region People's Hospital

    Nanning, China

  • The second affiliated Hospital of Guangxi Medical University

    Nanning, China

  • Nanyang Second General Hospital

    Nanyang, China

  • Ningbo First Hospital

    Ningbo, China

Showing 40 of 53 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.